DealLatus Bio, Inc., a Philadelphia-based gene therapy developer for Huntington’s, raised $97 million in a Series A fundraising round led by 8VC with participation from DCVC Bio and BioAdvance.
More on STAT+ →
SERIES A
05/11/2026
Uresta Resilia Inc., a Shediac, Canada-based femtech for bladder leaks,...
Helsing, a Munich-based defense AI company, raised $1.2 billion in a...
Autoimmunity BioSolutions, a Houston-based autoimmune disease therapeutics...
Veritas Aortic Solutions, a Costa Mesa, CA-based non-surgical aortic...
Psilera, a Tampa, FL-based psychedelic neuroplastogen therapeutics...
Gnosis Health, a Newcastle upon Tyne, United Kingdom-based Parkinson’s...
Stay informed on industry shifts, deal trends, and career opportunities in venture capital.
